Trial Profile
An open-label, two-period crossover study to evaluate the safety, tolerability, and pharmacokinetics of odanacatib and midazolam alone or after multiple doses of prednisone in healthy male volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2015
Price :
$35
*
At a glance
- Drugs Midazolam (Primary) ; Odanacatib (Primary) ; Prednisone
- Indications Osteoporosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Merck & Co
- 08 Dec 2015 New trial record